---
search:
  boost: 3
---

# Anti-Migraine Agents, Cluster Headache

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Tree

- [CNS - Anti-Migraine Agents, Cluster Headache - Emgality](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM0ZPTzBVSUc4NDYzOVZFMFVXM0hVOTYyVSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                    | Generic Name                                              |         Quantity          |        Time (Days)        |
| :------------------------------------------- | :-------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Verapamil <sup>QL</sup>                      | Verapamil HCI Tab (all strengths)                         |            408            |            102            |
| Verapamil CR (generic Calan) <sup>QL</sup>   | Verapamil HCI CR Tab (all strengths)                      |            204            |            102            |
| Verapamil ER (generic Verelan) <sup>QL</sup> | Verapamil HCI SR Cap (all strengths excl 200 MG & 240 MG) |            102            |            102            |
| Verapamil ER (generic Verelan) <sup>QL</sup> | Verapamil HCI SR Cap 200 MG & 240 MG                      |            204            |            102            |
| Verapamil (generic Verelan PM) <sup>QL</sup> | Verapamil HCI SR Cap (all strengths)                      | Determined pursuant to PA | Determined pursuant to PA |

### Non-Preferred

| Non-Preferred          | Generic Name                                                 |         Quantity          |        Time (Days)        |
| :--------------------- | :----------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Emgality <sup>QL</sup> | Galcanezumab Subcutaneous Inj (all strengths & formulations) | Determined pursuant to PA | Determined pursuant to PA |

## Authorizations

**Length of Authorizations**: 180 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^60 days^^ with at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- An inadequate clinical response to verapamil is defined as a titration to at least 480mg daily

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**QL** - Emgality: 3 doses per 30 days

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=27){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=14){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
